Oncomatryx Biopharma
Last verified 2026-05-08. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $2.7Mattributed |
|---|---|
| Latest round | strategic, $2.7M, 2025-03-01attributed |
| Founded | unknown |
| Headquarters | Derio, Spain |
| Industry | unknown |
| Stage | series-b+ |
| Website | oncomatryx.com |
Oncomatryx develops ADCs that target the tumour microenvironment and stroma rather than the tumour cells themselves to bypass resistance mechanisms. It targets metastatic solid tumours via clinical trials with stroma-directed payloads. The Bizkaia-based company frames the tumor stroma as the battlefield for next-generation oncology.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-03-01 | strategic | $2.7M | undisclosed |
Detected tech stack
WordPress 7.0, Apache HTTP Server, GeneratePress 3.6.1, jQuery Migrate 3.4.1, imagesLoaded 5.0.0, Elementor 3.35.5, WPML, Python, PHP, MySQL, jquery 3., apache
Provenance
| Fact | Status | Basis |
|---|---|---|
| Strategic, $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Total raised $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Company existence | self-reported | oncomatryx.com, read 2026-05-08 |
| Description | self-reported | oncomatryx.com, read 2026-05-08 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.